Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 8/20 | 0.39 |
| ▸ | PDE8B | O95263 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55228 | 0.77 | KDM4E (0.44) | PKMLPAR1CDK2KMT2AKDM4E | |
| SCHEMBL4759855 | 0.74 | KDM4E (0.41) | PKMLPAR1CDK2KMT2AKDM4E | |
| SCHEMBL7335690 | 0.73 | PKM (0.38) | PKMLPAR1 | |
| SCHEMBL25432012 | 0.71 | KMT2A (0.42) | PKMLPAR1CDK2KMT2AKDM4E | |
| SCHEMBL25432010 | 0.71 | KMT2A (0.42) | PKMLPAR1CDK2KMT2AKDM4E | |
| SCHEMBL1665273 | 0.70 | PKM (0.55) | PKMLPAR1CDK2KMT2AKDM4E | |
| SCHEMBL1664856 | 0.70 | PKM (0.41) | PKMLPAR1KMT2AKDM4EMEN1 | |
| SCHEMBL2076461 | 0.69 | PKM (0.57) | PKMLPAR1KMT2AKDM4EMEN1 | |
| SCHEMBL4758468 | 0.69 | KMT2A (0.43) | KMT2AKDM4EMEN1 | |
| SCHEMBL1718493 | 0.67 | PKM (0.51) | PKMLPAR1CDK2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060040959-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040959-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | PKM 2364/4885LPAR1 469/4885PDE8B 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.